X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-beigenes-esophageal-cancer-therapy-2024-03-14/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761232
https://www.prnewswire.com/news-releases/akeso-announced-the-first-patient-dosed-in-phase-iii-trial-of-cadonilimabpd-1ctla-4-combined-with-chemotherapy-versus-tislelizumab-combined-with-chemotherapy-in-first-line-treatment-of-pd-l1-negative-nsclc-302081234.html
https://www.prnewswire.com/news-releases/asieris-will-present-for-the-first-time-interim-analysis-data-of-oral-apl-1202-in-combination-with-pd-1-inhibitor-tislelizumab-for-neoadjuvant-treatment-of-muscle-invasive-bladder-cancer-at-2024-asco-gu-302044439.html
https://www.ema.europa.eu/en/documents/overview/tevimbra-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/after-tigit-divorce-novartis-returns-tislelizumab-beigene-pd-1-gains-first-european-nod
https://ir.beigene.com/news/beigene-announces-positive-regulatory-updates-in-europe-and-the-u-s-after-recently-regaining-global-rights/5e4692d6-d726-4989-a659-49dc97d4d7ed/
https://www.prnewswire.com/news-releases/akeso-announced-first-patient-dosed-in-phase-3-trial-of-ivonescimab-versus-tislelizumab-for-first-line-treatment-of-squamous-nsclc-301904377.html
https://www.globenewswire.com/news-release/2023/07/17/2705723/0/en/Immix-Biopharma-Reports-2nd-Positive-Interim-Clinical-Trial-Data-Readout-in-Relapsed-Refractory-Metastatic-Colorectal-Cancer-in-Ongoing-Phase-1b-2a-IMX-110-IMMINENT-01-Clinical-Tri.html
https://www.fiercepharma.com/pharma/beigene-novartis-tislelizumab-stages-comeback-broader-stomach-cancer-win
https://www.globenewswire.com/news-release/2023/04/04/2640577/0/en/Enlivex-Announces-Tislelizumab-Clinical-Collaboration-Full-Year-2022-Financial-Results-and-Provides-Business-Updates.html
https://www.globenewswire.com/news-release/2023/04/03/2639513/0/en/Enlivex-Announces-Clinical-Collaboration-to-Evaluate-Combinations-of-Allocetra-and-PD-1-Inhibitor-Tislelizumab-for-Patients-with-Solid-Tumors.html
https://www.contractpharma.com/contents/view_breaking-news/2023-04-03/enlivex-beigene-partner-to-evaluate-allocetrapd-1-inhibitor-tislelizumab/?widget=listSection
https://www.fiercepharma.com/pharma/beigene-doubles-sales-brukinsa-tislelizumab-gear-key-launches
https://www.globenewswire.com/news-release/2023/02/07/2602942/0/en/Immix-Biopharma-Announces-Dosing-of-First-2-Patients-in-its-IMX-110-BeiGene-Novartis-anti-PD-1-Tislelizumab-Phase-1b-2a-Combination-Clinical-Trial-in-Patients-with-Advanced-Cancer.html
https://www.businesswire.com/news/home/20221230005150/en/BeiGene-Announces-Acceptance-of-12th-Regulatory-Submission-in-China-for-PD-1-Inhibitor-Tislelizumab
https://www.globenewswire.com/news-release/2022/12/19/2576254/0/en/ImmixBio-Ships-Tislelizumab-for-Patient-Dosing-in-its-Combination-Clinical-Trial-with-IMX-110-in-Advanced-Solid-Tumors.html
https://www.clinicaltrialsarena.com/news/asieris-bladder-cancer-trial/
https://www.globenewswire.com/news-release/2022/12/13/2572651/0/en/Immix-Biopharma-Announces-Patient-Dosing-in-Ongoing-Phase-1b-2a-IMX-110-Monotherapy-Clinical-Trial.html
https://www.prnewswire.com/news-releases/asieris-enrolled-first-patient-for-its-phase-ii-clinical-study-of-oral-apl-1202-in-combination-with-tislelizumab-a-pd-1-inhibitor-as-neoadjuvant-therapy-for-muscle-invasive-bladder-cancer-301700090.html
https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-clinical-supply-agreement-with-beigene-to-evaluate-pt199-in-combination-with-tislelizumab-301698698.html
https://www.novartis.com/news/media-releases/novartis-announces-tislelizumab-demonstrated-efficacy-and-tolerability-first-line-advanced-liver-cancer-phase-iii-trial
https://endpts.com/beigene-touts-positive-phiii-data-on-tislelizumab-in-aftermath-of-fda-rejection/
https://www.clinicaltrialsarena.com/news/beigene-tislelizumab-hepatocellular-cancer/
https://www.fiercepharma.com/pharma/novartis-shelves-tislelizumab-fda-submission-monotherapy-non-small-cell-lung-cancer
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-delays-decision-beigenes-cancer-drug-covid-restrictions-2022-07-14/
https://www.globenewswire.com/news-release/2022/06/30/2471828/0/en/New-Phase-III-data-show-Novartis-tislelizumab-significantly-extended-median-overall-survival-by-more-than-6-months-in-first-line-advanced-esophageal-cancer-in-combination-with-chem.html
https://www.prnewswire.com/news-releases/asieris-to-present-a-study-protocol-of-apl-1202-in-combination-with-beigenes-tislelizumab-as-neoadjuvant-therapynacfor-muscle-invasive-bladder-cancer-mibc-patients-at-2022-asco-annual-meeting-301556690.html
https://www.fiercepharma.com/pharma/novartis-shows-data-could-help-win-approval-beigene-pd-1-drug-us
https://www.pharmaceutical-technology.com/news/beigene-tislelizumab-oesophageal-cancer/
https://www.fiercepharma.com/pharma/what-fda-crackdown-novartis-oncology-chief-touts-beigene-pd-1-s-global-profile
Market Place
Share 
